Home > Cardiology > ACC 2022 > Interventional and Structural Cardiology > Plot twist for negative FAME 3 results: early QoL benefits of PCI

Plot twist for negative FAME 3 results: early QoL benefits of PCI

Presented By
Dr Frederik Zimmermann, Catharina Hospital, the Netherlands
Conference
ACC 2022
Trial
FAME 3
The FAME 3 trial previously failed to meet its criteria for non-inferiority comparing percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) with coronary artery bypass grafting (CABG) for treating 3-vessel coronary artery disease. A new subanalysis suggests that PCI may be associated with early improvements in quality of life; however, results did not extend out to 1 year. The full FAME 3 study (NCT02100722), published recently in the New England Journal of Medicine, reported that in patients with 3-vessel coronary artery disease, FFR-guided PCI (n=757) was not better than CABG (n=743) with respect to the incidence of a composite of death, myocardial infarction, stroke, or repeat revascularisation at 1 year [1]. At the ACC 2022, Dr Frederik Zimmermann (Catharina Hospital, the Netherlands) presented the results of a QoL suban...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on